Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma

Next Previous
Search
Trial Profile

Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Trametinib (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Pancreatic cancer
  • Focus Adverse reactions

Most Recent Events

  • 09 Oct 2023 Planned End Date changed from 1 Mar 2023 to 31 Mar 2024.
  • 10 Jun 2022 Planned End Date changed from 30 Jun 2022 to 1 Mar 2023.
  • 10 Jun 2022 Planned primary completion date changed from 30 Jun 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top